Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice This open-label, ...

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients with prostate cancer.

As someone who has firsthand experience scaling a company sustainably, I have witnessed the profound impact that the organizational structure can have on long-term success. Through my experiences ...

Padcev (enfortumab vedotin-ejfv) is a brand-name infusion prescribed for urothelial cancer (a type of bladder cancer). As with other drugs, Padcev can cause side effects, such as rash and hair loss.

The positive opinion comes just one week after Keytruda was approved by the Medicines and Healthcare products Regulatory Agency in combination with Astellas/Pfizer’s Padcev (enfortumab vedotin) as a ...

HSBC is simplifying its organizational structure into four businesses to streamline its businesses and reduce costs months after its new chief executive took over reins. Europe's largest bank by ...

November 4th 2022EP. 3: EV+P Combination Strategy Changing Bladder Cancer Treatment Landscape Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV ™ (enfortumab vedotin, an antibody-drug conjugate ...

Capital structure describes the mix of a firm's long-term capital—a mix of debt and equity—that it uses to fund its ongoing operations and future growth. A company's capital structure is ...

The 2-year progression-free survival rate was 92% with nivolumab plus AVD and 83% with brentuximab vedotin plus AVD. Nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD) improved ...

The incorporation of the CD30-directed antibody drug conjugate brentuximab vedotin into the treatment of advanced-stage Hodgkin’s lymphoma has led to improved outcomes. 11 Modified progression ...